JP2024519335A5 - - Google Patents
Info
- Publication number
- JP2024519335A5 JP2024519335A5 JP2023569939A JP2023569939A JP2024519335A5 JP 2024519335 A5 JP2024519335 A5 JP 2024519335A5 JP 2023569939 A JP2023569939 A JP 2023569939A JP 2023569939 A JP2023569939 A JP 2023569939A JP 2024519335 A5 JP2024519335 A5 JP 2024519335A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- dose
- pharmaceutical composition
- fludarabine
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163201792P | 2021-05-13 | 2021-05-13 | |
| US63/201,792 | 2021-05-13 | ||
| US202263269316P | 2022-03-14 | 2022-03-14 | |
| US63/269,316 | 2022-03-14 | ||
| PCT/US2022/028839 WO2022241036A1 (en) | 2021-05-13 | 2022-05-11 | Dosing regimens for cancer immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519335A JP2024519335A (ja) | 2024-05-10 |
| JP2024519335A5 true JP2024519335A5 (https=) | 2025-05-19 |
Family
ID=84029831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569939A Pending JP2024519335A (ja) | 2021-05-13 | 2022-05-11 | がん免疫療法のための投薬レジメン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250073266A1 (https=) |
| EP (1) | EP4337228A4 (https=) |
| JP (1) | JP2024519335A (https=) |
| KR (1) | KR20240032732A (https=) |
| AU (1) | AU2022272973A1 (https=) |
| CA (1) | CA3218640A1 (https=) |
| WO (1) | WO2022241036A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| DE102022132084B4 (de) | 2022-12-02 | 2024-08-22 | Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) | Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür |
| DE102022132083B4 (de) | 2022-12-02 | 2024-08-22 | Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) | Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür |
| DE102022132082B4 (de) | 2022-12-02 | 2024-08-08 | Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) | Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung. |
| WO2025006631A1 (en) * | 2023-06-27 | 2025-01-02 | Nkarta, Inc. | Dosing regimens for treatment of cancer |
| CN117430721B (zh) * | 2023-10-25 | 2024-06-25 | 北京景达生物科技有限公司 | Cd123靶向car-nk细胞的制备及其应用 |
| WO2025106552A1 (en) * | 2023-11-14 | 2025-05-22 | Nkarta, Inc. | Methods and compositions for treatment of leukemia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130296273A1 (en) * | 2010-06-28 | 2013-11-07 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
| WO2014066137A1 (en) * | 2012-10-22 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for enhancing cancer immunotherapy |
| KR101862955B1 (ko) * | 2013-12-05 | 2018-05-31 | 에프. 호프만-라 로슈 아게 | 급성 골수성 백혈병(aml)을 위한 신규한 병용 치료 |
| BR112019019917A2 (pt) * | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| AU2019337603B2 (en) * | 2018-09-13 | 2026-03-05 | Nkarta, Inc. | Natural killer cell compositions and immunotherapy methods for treating tumors |
| EP3773918A4 (en) * | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| CA3148179A1 (en) * | 2019-08-20 | 2021-02-25 | Bruce J. Mccreedy Jr. | Lymphodepletion dosing regimens for cellular immunotherapies |
-
2022
- 2022-05-11 EP EP22808293.9A patent/EP4337228A4/en active Pending
- 2022-05-11 CA CA3218640A patent/CA3218640A1/en active Pending
- 2022-05-11 WO PCT/US2022/028839 patent/WO2022241036A1/en not_active Ceased
- 2022-05-11 US US18/559,514 patent/US20250073266A1/en active Pending
- 2022-05-11 KR KR1020237043009A patent/KR20240032732A/ko active Pending
- 2022-05-11 JP JP2023569939A patent/JP2024519335A/ja active Pending
- 2022-05-11 AU AU2022272973A patent/AU2022272973A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024519335A5 (https=) | ||
| JP2023518049A5 (https=) | ||
| IL273201B1 (en) | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| JP2021500861A5 (https=) | ||
| JP2021525509A5 (https=) | ||
| JP2024518011A5 (https=) | ||
| US20200038443A1 (en) | Multi-function and multi-targeting car system and methods for use thereof | |
| WO2020247392A1 (en) | Combinations of engineered natural killer cells and engineered t cells for immunotherapy | |
| US20230028399A1 (en) | Bcma-directed cellular immunotherapy compositions and methods | |
| JP2022545167A5 (https=) | ||
| JP2020517263A5 (https=) | ||
| US20250073266A1 (en) | Dosing regimens for cancer immunotherapy | |
| EP3612222A1 (en) | Compositions and methods for treating cancer | |
| US20250319185A1 (en) | Bcma-directed cellular immunotherapy compositions and methods | |
| IL297514A (en) | Vectors and methods for in vivo transduction | |
| JP2023525720A5 (https=) | ||
| JP2024510900A5 (https=) | ||
| US20230398216A1 (en) | Chimeric activation receptors | |
| WO2022222845A1 (zh) | 混合的固有淋巴细胞、制备方法及其应用 | |
| WO2023207390A1 (zh) | 一种ciita基因被敲除的工程化免疫细胞及其用途 | |
| JP2022516710A5 (https=) | ||
| JP2025524564A (ja) | Ｃｄ１９指向性がん免疫療法の投与レジメン | |
| US20210079111A1 (en) | Cd19-cd20 bispecific and dual passway car-t and methods for use thereof | |
| JP2019531742A5 (https=) |